Innovating to Bring Important New Therapies to Patients
Pfizer’s purpose is to innovate to bring therapies that significantly improve patients' lives. R&D is at the heart of fulfilling Pfizer’s purpose as we work to translate advanced science and technologies into the therapies that matter most.
Today, we are at a unique moment in biomedical innovation. More than a decade after the decoding of the human genome, we have a fundamentally better understanding of human biology and what causes disease. We have also learned that it takes more than just great science to deliver meaningful new therapies. Over the last few years, Pfizer has taken a hard look at the way we did R&D in the past. We have better integrated science and business, which meant transforming our approach to be more collaborative, more focused, and, we believe, more powerful for patients. Ultimately, we’ve worked to design an engine that can deliver patients a sustainable flow of important new medicines and vaccines, year after year.
We focus our efforts in core areas where we believe Pfizer is best positioned to bring unique, needed therapies to patients. This includes chronic inflammatory and autoimmune diseases, vaccines, oncology, neuroscience and pain, cardiovascular and metabolic disease and rare diseases. We bring to these areas, cutting-edge capabilities in medicine and vaccine design and development.
Key to our approach is collaborating in new and dynamic ways with other innovators across the health landscape including academic scientists, patient foundations, governments, other biopharmaceutical companies and treating physicians.
Today our pipeline is comprised of over 80 innovative therapies including potentially first-in-class vaccines for two deadly hospital-acquired infections, new antibodies for lupus and high cholesterol and the next-generation of targeted therapies for cancer. We are also building upon a heritage of developing safe and effective biologic medicines to introduce high-quality biosimilars that can broaden patient access with lower-cost alternative biologic therapies.
We invite you to learn more.
Mikael Dolsten, M.D., Ph.D.
President – Worldwide Research and Development